Biotechnology Bulletin ›› 2022, Vol. 38 ›› Issue (12): 137-143.doi: 10.13560/j.cnki.biotech.bull.1985.2022-0238

Previous Articles     Next Articles

Research Progress in Vero Cell-based Influenza Vaccine

MA Fang-fang1,3(), KANG Bi-jing1,3, MA Chun-ying1,3, LIU Zhen-bin1,2, YANG Di1,2, QIAO Zi-lin1,2, WANG Ming-ming1,3, MA Zhong-ren1,2, WANG Jia-min1,2()   

  1. 1. Gansu Tech Innovation Center of Animal Cell,Biomedical Research Center,Northwest Minzu University,Lanzhou 730030
    2. Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission,Biomedical Research Center,Northwest Minzu University,Lanzhou 730030
    3. Life Science and Engineering College of Northwest Minzu University,Lanzhou 730030
  • Received:2022-02-26 Online:2022-12-26 Published:2022-12-29
  • Contact: WANG Jia-min E-mail:3535205030@qq.com;jiaminwang1987@163.com

Abstract:

The prevention of influenza is one of the most severe challenges faced by mankind. Influenza vaccine inoculation is the key of preventing influenza. There are limitations in the traditional production process of influenza vaccine due to its dependence on chicken embryo, and the production of large-scale influenza vaccine is gradually transferred from chicken embryo to mammalian cells. Currently, MDCK, Vero and PER.C6 cell lines can be used for influenza vaccine development. Vero cells have non-tumogenesis within a certain range of generations and been used in the production of a variety of human viral vaccines. It is the cell line recommended by WHO that is widely used in the production of human and animal virial vaccines, however, there is still challenges in the Vero cell-based influenza vaccine production. This paper reviews the research of influenza vaccine, the comprehensive comparison of cell-based influenza vaccine and the difficulties faced by Vero cells in the production of influenza vaccine, aiming to provide reference for the development of cell-based influenza vaccine.

Key words: influenza, Vero cell, vaccine, suspension culture